Hans-Peter Kiem, MD, Dr.Med.
NGEC Principal Investigator
Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
Investigator, Markey Molecular Medicine Center, University of Washington
Professor, University of Washington School of Medicine
Adjunct Professor of Pathology, University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N., D1-100
PO Box 19024
Seattle, WA 98109-1024
Tel: 206-667-4425; Fax: 206-667-6124
Dr. Kiem is a full member at the Fred Hutchinson Cancer Research Center; an investigator at the Markey Molecular Medicine Center; Professor of Medicine at the University of Washington; and Adjunct Professor of Pathology at the University of Washington. His laboratory studies stem cell biology and stem cell gene transfer with the goal of developing novel stem cell–based treatment strategies for patients with genetic, infectious and malignant diseases. Current research in his laboratory focuses on stem cell biology/transplantation and gene therapy studies to: 1) characterize HSCs from large animal models; 2) develop preclinical protocols using stem cell gene therapy to facilitate allogeneic nonmyeloablative stem cell transplantation; and 3) develop clinical gene therapy protocols for genetic and acquired diseases including cancer.
Dr. Kiem is the principal investigator for the NGEC in the area of gene repair in canine immunodeficiency models.
Awards and Honors
- Fellowship from the Deutsche Krebshilfe (German Cancer Aid): 1988
- Markey Charitable Trust Award: 1995
- Editorial Board Memberships: Blood (2002–present); Molecular Therapy (2003–present); Gene Therapy (2003–present)
- Member, Immunology and Hematopoietic Cell Gene Therapy Committee, American Society of Gene Therapy: 2003-2006
- Chair, Gene Therapy Subcommittee, International Society for Cellular Therapy: 2004
- Member, Developmental Therapeutics Study Section: 2004–present
- Member, American Society of Clinical Investigation: 2005–present
Areas of Expertise
- Stem cell biology/transplantation
- Gene therapy
- Vector development
- Characterize HSCs from large animal models
- Analyze the clonal composition of hematopoiesis after transplantation of gene-modified HSCs
- Develop novel vector systems for improved gene delivery
- Study retroviral integration sites and insertional mutaganesis
- Stem cell expansion and cord blood transplantation
- Nonhuman primate embryonic stem cells
- Develop pre-clinical protocols using stem cell gene therapy to facilitate allogeneic nonmyeloablative stem cell transplantation
- Develop clinical gene therapy protocols for brain tumors, Fanconi anemia and AIDS
Overview of the Kiem Lab
The main focus of the Kiem Laboratory is to study stem cell biology and stem cell gene transfer with the goal of developing novel stem cell–based treatment strategies for patients with genetic, infectious and malignant diseases.
Dr. Kiem and his team will initiate studies of LHE-based gene modification in canine hematopoietic stem cells as an initial step towards translation of gene repair of hematopoietic cells to humans. These studies will involve the following specific aims:
- The Kiem lab will evaluate initial and stable genomic marking at endogenous and artificial reporter loci in canine hematopoietic stem cells using NIL lentiviral vectors expressing available LHEs.
- Using marking conditions established in Aim #1, the Kiem Lab will evaluate non-myeloablative conditioning regimens and a “knock-in” approach with an in vivo selectable marker system.
- Using the methods developed in the above aims, the Kiem Lab will pilot gene repair of the naturally-arising canine lymphohematopoietic diseases XSCID and PK deficiency. These studies will involve generation via the NGEC Cell and Virus CORE of appropriate NIL vectors expressing LHEs (designed in Aim #1) which cut at the XSCID and PK loci, followed by use of these vectors for stem cell transduction, and evaluation of the efficacy of correction of the canine XSCID and PK disease phenotypes.
Key personnel carrying out this research include Nina Munoz (postdoctoral fellow) and Brian Beard (associate in clinical research).